Jun Liang

发表

Staphylococcus aureus adhesion to different implant surface coatings: An in vitro study

Xiaojing Wang, Guowei Wang, Jun Liang, 2009 .

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.

Adam R. Johnson, Jun Liang, J. DeVoss, 2013, Journal of medicinal chemistry.

Lead identification of novel and selective TYK2 inhibitors.

Adam R. Johnson, Jun Liang, M. Ultsch, 2013, European journal of medicinal chemistry.

A new regulatory switch in a JAK protein kinase

Charles Eigenbrot, Vickie Tsui, Paul Gibbons, 2011, Proteins.

A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.

Jennafer Dotson, Christian Wiesmann, Jason Drummond, 2009, Journal of medicinal chemistry.

Crystal structure of GDC-0927 bound to estrogen receptor alpha

Siew K. Yeap, N. C. Ray, Jun Liang, 2019 .

Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.

Jun Liang, J. Blake, B. Brandhuber, 2012, Journal of medicinal chemistry.

Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.

Jun Liang, Y. Ran, L. Friedman, 2020, ACS medicinal chemistry letters.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Adam R. Johnson, Jun Liang, J. DeVoss, 2017, Bioorganic & medicinal chemistry letters.

The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.

Jun Liang, R. Robinson, S. F. Barnett, 2008, Bioorganic & medicinal chemistry letters.

Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain.

Jun Liang, J. W. Tarpley, M. Fisher, 2005, Bioorganic & medicinal chemistry letters.

Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain.

Jun Liang, J. W. Tarpley, M. Fisher, 2005, Bioorganic & medicinal chemistry letters.

Discovery of Inhibitors of the Lipopolysaccharide Transporter MsbA: From a Screening Hit to Potent Wild-Type Gram-Negative Activity.

Benjamin D. Sellers, Jun Liang, C. Koth, 2022, Journal of medicinal chemistry.

Steric and Electronic Factors Influence Regio‐isomeric Thiazole Formations Between Substituted Benzothioamides and Ethyl Bromopyruvate

Jun Liang, Birong Zhang, Yingjie Lai, 2014 .

Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity.

Hoai An Le Thi, Jun Liang, Y. Ran, 2019, ACS medicinal chemistry letters.

Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.

Jun Liang, E. Hu, P. Prasit, 2009, Bioorganic & medicinal chemistry letters.

A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.

Guy Georges, Elizabeth Blackwood, Christian Wiesmann, 2008, Journal of medicinal chemistry.

A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors

Adam R. Johnson, Jun Liang, N. Lewin-Koh, 2013, The Journal of Immunology.

Monomeric targeted protein degraders.

Jun Liang, R. Blake, N. Blaquière, 2020, Journal of medicinal chemistry.

Structural basis for dual-mode inhibition of the ABC transporter MsbA

Benjamin D. Sellers, Jun Liang, Y. Franke, 2018, Nature.

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

Siew K. Yeap, N. C. Ray, Jun Liang, 2021, Journal of medicinal chemistry.

Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.

Jun Liang, P. Trojer, R. Cummings, 2016, Bioorganic & medicinal chemistry letters.

From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

Jun Liang, P. Trojer, Y. Ran, 2017, Bioorganic & medicinal chemistry letters.

Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.

Jun Liang, P. Trojer, R. Cummings, 2016, Bioorganic & medicinal chemistry letters.

Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors.

Jun Liang, R. Robinson, S. F. Barnett, 2008, Bioorganic & medicinal chemistry letters.

Mass Spectrometric Quantification of Histone Post-translational Modifications by a Hybrid Chemical Labeling Method

Jun Liang, A. Masselot, P. Trojer, 2015, Molecular & Cellular Proteomics.

Discovery of GNE-502 as an Orally Bioavailable and Potent Degrader for Estrogen Receptor Positive Breast Cancer.

Jun Liang, Y. Ran, L. Friedman, 2021, Bioorganic & medicinal chemistry letters.

Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.

Jun Liang, J. Nwachukwu, K. Nettles, 2019, Bioorganic & medicinal chemistry letters.

cis-Selective synthesis of 1,3-disubstituted tetrahydro-β-carbolines from N-sulfonyl N,S-acetals.

Jun Liang, D. Ortwine, Yanzhou Liu, 2019, Organic & biomolecular chemistry.

Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927

Jun Liang, A. Daemen, Andiliy G. Lai, 2018, Cancer Chemistry.

DESIGN, SYNTHESIS, AND KINETIC EVALUATION OF HIGH-AFFINITY FKBP LIGANDS AND THE X-RAY CRYSTAL-STRUCTURES OF THEIR COMPLEXES WITH FKBP12.

Jon Clardy, J. Luengo, L. Rozamus, 1994 .

A new regulatory switch in a JAK protein kinase

Jun Liang, M. Ultsch, M. Lamers, 2011, Proteins.

Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927.

Siew K. Yeap, N. C. Ray, Jun Liang, 2019, Bioorganic & medicinal chemistry letters.